Skip to content

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
5.5×-0.3×
AbbVie logo
AbbVieABBV
0.8×0.0×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
15.1×+10.0×

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

Based on the most recent quarter.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s current ratio?
SELLAS Life Sciences Group, Inc. (SLS) reported current ratio of 17.2× in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s current ratio changed year-over-year?
SELLAS Life Sciences Group, Inc.'s current ratio increased by 271.0% year-over-year, from 4.6× to 17.2×.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s current ratio?
Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s current ratio has grown at a 29.1% compound annual growth rate (CAGR), from 3× to 10.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.